Recombinant RFB4 immunotoxins exhibit potent cytotoxic activity for CD22-bearing cells and tumors

Blood

Volumn 90, Issue 5, 1997, Pages 2020-2026

  Mansfield, Elizabeth ^b   Amlot, Peter ^b   Pastan, Ira ^b   FitzGerald, David J ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CD22 ANTIGEN; IMMUNOTOXIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY RFB 4; PSEUDOMONAS EXOTOXIN; RICIN A; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; B CELL LEUKEMIA; B CELL LYMPHOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; TARGET CELL;

EID: 0030954684     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v90.5.2020     Document Type: Article

References (21)

1. Amlot P, Stone MJ, Cunningham D, Fay J, Newman J, Collins R, May R, McCarthy M, Richardson J, Ghetie V, Ramilo O, Thorpe PE, Uhr JW, Vitetta ES: A phase I study of anti-CD22 deglycosylated ricin A chain immunotoxin in the treatment of B cell lymphomas resistant to conventional therapy. Blood 82:2624, 1993
2. Sausville EA, Headlee D, Stetler-Stevenson M, Jaffe ES, Solomon D, Figg WD, Herdt J, Kopp WC, Rager H, Steinberg SM, Ghetie V, Schindler J, Uhr J, Wittes RE, Vitetta ES: Continuous infusion of the anti-CD22 immunotoxin IgG-RFB4-SMPT-dgA in patients with B-cell lymphoma: A phase I study. Blood 85:3457, 1995
3. Grossbard ML, Gribben JG, Freedman AS, Lambert JM, Kinsella J, Rabinowe SN, Eliseo L, Taylor JA, Blattler WA, Epstein CL, Nadler LM: Adjuvant immunotoxin therapy with anti-B4-blocked ricin after autologous bone marrow transplantation for patients with B-cell non-Hodgkin's lymphoma. Blood 81:2263, 1993
4. Grossbard ML, Lambert JM, Goldmacher VS, Spector NL, Kinsella J, Eliseo L, Coral F, Taylor JA, Blattler WA, Epstein CL, Nadler L: Anti-B4-blocked ricin: A phase I trial of 7-day continuous infusion in patients with B-cell neoplasms. J Clin Oncol 11:726, 1993
5. Uckun FM, Manivel C, Arthur D, Chelstrom LM, Finnegan D, Tuel-Ahlgren L, Irvin JD, Myers DE, Gunther R: In vivo efficacy of B43 (anti-CD19)-pokeweed antiviral protein immunotoxin against human pre-B cell acute lymphoblastic leukemia in mice with severe combined immunodeficiency. Blood 79:2201, 1992
6. Ghetie M-A, Richardson J, Tucker T, Jones D, Uhr JW, Vitetta ES: Antitumor activity of Fab′ and IgG-anti-CD22 immunotoxins in disseminated human B lymphoma grown in mice with severe combined immunodeficiency disease: Effect on tumor cells in extranodal sites. Cancer Res 51:5876, 1991
7. Francisco JA, Gilliland LK, Stebbins MR, Morris NA, Ledbetter JA, Siegall CB: Activity of a single-chain immunotoxin that selectively kills lymphoma and other B-lineage cells expressing the CD40 antigen. Cancer Res 55:3099, 1995
8. Vaickus L, Ball ED, Foon KA: Immune markers in hematologic malignancies. Crit Rev Oncol Hematol 11:267, 1991
9. Li J-L, Shen G-L, Ghetie M-A, May RD, Till M, Ghetie V, Uhr JW, Janossy G, Thorpe PE, Amlot P, Vitetta ES: The epitope specificity and tissue reactivity of four murine monoclonal anti-CD22 antibodies. Cell Immunol 118:85, 1989
10. Ghetie M-A, May RD, Till M, Uhr JW, Ghetie V, Knowles PP, Relf M, Brown A, Wallace PM, Janossy G, Amlot P, Vitetta ES, Thorpe PE: Evaluation of ricin A chain-containing immunotoxins directed against CD19 and CD22 antigens on normal and malignant human B-cells as potential reagents for in vivo therapy. Cancer Res 48:2610, 1988
11. Mansfield E, Pastan I, FitzGerald DJ: Characterization of RFB4-PE immunotoxins targeted to CD22 on B-cell malignancies. Bioconjug Chem 7:557, 1996
12. Debinski W, Pastan I: Monovalent immunotoxin containing truncated form of Pseudomonas exotoxin as potent antitumor agent. Cancer Res 52:5379, 1992
13. Brinkmann U, Pastan I: Recombinant immunotoxins: From basic research to cancer therapy. Methods 8:143, 1995
14. Reiter Y, Brinkmann U, Lee B-K, Pastan I: Engineering antibody fragments for cancer detection and therapy: Disulfide-stabilized Fv fragments. Nat Biotechnol 14:1239, 1996
15. Benhar I, Pastan I: Cloning, expression and characterization of the Fv fragments of the anti-carbohydrate mAbs B1 and B5 as single-chain immunotoxins. Protein Eng 7:1509, 1994
16. Studier FW, Moffatt BA: Use of bacteriophage T7 polymerase to direct selective expression of cloned genes. J Mol Biol 189:113, 1986
17. Buchner J, Pastan I, Brinkmann U: A method for increasing the yield of properly folded recombinant fusion proteins: Single-chain immunotoxins from renaturation of bacterial inclusion bodies. Anal Biochem 205:263, 1992
18. Jung S-H, Pastan I, Lee B: Design of interchain disulfide bonds in the framework region of the Fv of the monoclonal antibody B3. Proteins: Structure, Function and Genetics. 19:35, 1994
19. Reiter Y, Brinkmann U, Webber K, Jung S-H, Lee B, Pastan I: Engineering interchain disulfide bonds into conserved framework regions of Fv fragments: Improved biochemical characteristics of recombinant immunotoxins containing disulfide-stabilized Fv. Protein Eng 7:697, 1994
20. Reiter Y, Brinkmann U, Kreitman RJ, Jung SH, Lee B, Pastan I: Stabilization of the Fv fragments in recombinant immunotoxins by disulfide bonds engineered into conserved framework regions. Biochemistry 33:5451, 1994
21. Reiter Y, Brinkmann U, Jung SH, Lee B, Kasprzyk PG, King CR, Pastan I: Improved binding and antitumor activity of a recombinant anti-erbB2 immunotoxin by disulfide stabilization of the Fv fragment. J Biol Chem 269:18327, 1994